Adaptimmune Therapeutics plc
ADAP
$0.2223
$0.00733.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -70.81M | -44.52M | -72.50M | -163.41M | -113.87M |
| Total Depreciation and Amortization | 11.23M | 11.26M | 11.34M | 10.83M | 9.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.36M | 13.82M | 10.19M | -11.02M | -11.90M |
| Change in Net Operating Assets | -36.98M | -34.25M | 6.59M | 28.06M | -24.95M |
| Cash from Operations | -73.21M | -53.68M | -44.39M | -135.55M | -140.88M |
| Capital Expenditure | -886.00K | -1.49M | -1.64M | -2.43M | -4.68M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | 0.00 | 45.26M | 45.26M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.07M | 2.57M | 126.04M | 85.01M | 135.96M |
| Cash from Investing | -58.95M | 1.08M | 124.40M | 127.84M | 176.54M |
| Total Debt Issued | 49.50M | 49.50M | 24.50M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 29.25M | 29.32M | 29.92M | 29.92M | 880.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 78.75M | 78.82M | 54.42M | 29.92M | 880.00K |
| Foreign Exchange rate Adjustments | -402.00K | 128.00K | 43.00K | -127.00K | 877.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.81M | 26.35M | 134.48M | 22.08M | 37.42M |
